News

Find out more about us and our portfolio companies

All years

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2026/09/16
Polaris Electro-Optics Secures $50M Series B to Scale Next-Gen Optical Engine Platform for AI Infrastructure

Series B led by Walden Catalyst Ventures will bring the company's FenGlass™ modulator platform to production for next-generation optical interconnects.
2026/09/15
Cyllene Therapeutics Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EG110A in Neurogenic Detrusor Overactivity (NDO)

RMAT designation follows proof of concept demonstration of strong, lasting efficacy and good safety profile in initial NDO Phase 1b/2a trial ongoing in the US.
EG110A is the first non-systemic, site-specific inhibitor of CGRP+ neurons, with initial applications to treat severe bladder disorders. A single treatment course could potentially provide long-lasting symptomatic relief in patients.

2026/09/16
Polaris Electro-Optics Secures $50M Series B to Scale Next-Gen Optical Engine Platform for AI Infrastructure
2026/09/15
Cyllene Therapeutics Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EG110A in Neurogenic Detrusor Overactivity (NDO)
2026/09/11
Actithera significantly strengthens leadership team and Board as Company advances towards clinical development
2026/09/10
TwoStep Therapeutics Announces Oversubscribed $62.5 Million Series A Financing and FDA Clearance of IND for First-in-Class Peptide-Drug Conjugate
2026/08/25
Quintessent Raises $40 Million Series A and Begins Sampling First Product for AI Optical Interconnects
2026/08/12
Remepy Raises $36 Million Series A to Expand Its Hybrid Drug™ Pipeline Through Pharmaceutical Partnerships and Advance Phase III of Hybridopa™ for Parkinson's Disease
2026/07/24
Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
2026/07/07
M Ventures co-leads Cyllene Therapeutics' €33 million Series C raise alongside GordonMD.
2026/06/19
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody
2026/06/01
Nouscom Receives U.S. FDA Fast Track Designation for NOUS-209, a Novel Immunotherapy for the Prevention of Lynch Syndrome-Associated Cancers
2026/05/26
Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer
2026/05/23
STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026
2026/05/12
Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases
2026/04/28
Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer
2026/04/17
STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15
2026/04/15
Lightcast Raises $27 Million and Adds Industry Veteran to Accelerate Commercialization of Envisia™ Platform
2026/03/20
Repronovo Appoints Mark Altmeyer as Chairman of the Board
2026/03/18
Enara Bio to Unveil First‑in‑Class DARKFOX‑Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential for Solid Tumor Immunotherapy
2026/03/18
Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer and appoints renowned E3 ligase experts to Scientific Advisory Board (SAB)
2026/03/02
Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer
2026/02/26
Celebrate women in science with Optimum
2026/02/23
Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer
2026/01/29
Concerto Biosciences Signs Development and Commercialization Agreement with Sacco System to Advance Next-Generation Microbial Ingredient Discovery
2026/01/29
UNISERS Ships First Fully-Automated Fab Tool and Strengthens Leadership to Scale In-Fab Deployment
2026/01/16
SEEQC and Allegro Merger Corp. Enter Into Merger Agreement
2026/01/16
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
2026/01/13
Altoida and Mindspan Announce Research Collaboration to Use AI/AR-Powered Digital Cognitive Assessment to Personalize Cognitive Care
2026/01/12
Iktos named Top BioTech and Life Sciences Companies of 2025
2026/01/12
Iktos Enters Strategic €1B+ Multi-Target AI Partnership with Servier to Advance Drug Discovery in Oncology and Neurology
2026/01/09
Pierre Fabre Laboratories and Iktos announce Integrated Drug Discovery Collaboration
2026/01/09
DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies
2026/01/09
M Ventures: Pharma CVC and biotech innovation in 2026
2026/01/08
NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s

Find out more about us and our portfolio companies

Polaris Electro-Optics Secures $50M Series B to Scale Next-Gen Optical Engine Platform for AI Infrastructure

Cyllene Therapeutics Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EG110A in Neurogenic Detrusor Overactivity (NDO)

Polaris Electro-Optics Secures $50M Series B to Scale Next-Gen Optical Engine Platform for AI Infrastructure

Cyllene Therapeutics Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EG110A in Neurogenic Detrusor Overactivity (NDO)

Actithera significantly strengthens leadership team and Board as Company advances towards clinical development

TwoStep Therapeutics Announces Oversubscribed $62.5 Million Series A Financing and FDA Clearance of IND for First-in-Class Peptide-Drug Conjugate

Quintessent Raises $40 Million Series A and Begins Sampling First Product for AI Optical Interconnects

Remepy Raises $36 Million Series A to Expand Its Hybrid Drug™ Pipeline Through Pharmaceutical Partnerships and Advance Phase III of Hybridopa™ for Parkinson's Disease

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

M Ventures co-leads Cyllene Therapeutics' €33 million Series C raise alongside GordonMD.​ ​

LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody

Nouscom Receives U.S. FDA Fast Track Designation for NOUS-209, a Novel Immunotherapy for the Prevention of Lynch Syndrome-Associated Cancers

Artios Announces First Patient Dosed in Randomized Phase 2 POLKA Study Evaluating DNA Polymerase Theta Inhibitor ART6043 in gBRCA-mutated HER2-Negative Breast Cancer

STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026

Boehringer Ingelheim licenses preclinical antibody program from Immunitas Therapeutics to advance treatments for chronic inflammatory diseases

Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer

STORM Therapeutics Secures $56 Million Series C Financing and Doses First Patient in Phase 2 Sarcoma Trial of STC‑15

Lightcast Raises $27 Million and Adds Industry Veteran to Accelerate Commercialization of Envisia™ Platform

Repronovo Appoints Mark Altmeyer as Chairman of the Board

Enara Bio to Unveil First‑in‑Class DARKFOX‑Targeting Bispecific T Cell Engager ENA101 in Oral Presentation at AACR 2026, Showcasing Breakthrough Potential for Solid Tumor Immunotherapy

Outrun Therapeutics unveils lead programme targeting HPV positive head and neck cancer and appoints renowned E3 ligase experts to Scientific Advisory Board (SAB)

Artios Reports Randomized Phase 2a Study of Low Dose Alnodesertib Plus Gemcitabine Achieves Primary Endpoint in Platinum-Resistant Ovarian Cancer

Celebrate women in science with Optimum

Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer

Concerto Biosciences Signs Development and Commercialization Agreement with Sacco System to Advance Next-Generation Microbial Ingredient Discovery

UNISERS Ships First Fully-Automated Fab Tool and Strengthens Leadership to Scale In-Fab Deployment

SEEQC and Allegro Merger Corp. Enter Into Merger Agreement

Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication

Altoida and Mindspan Announce Research Collaboration to Use AI/AR-Powered Digital Cognitive Assessment to Personalize Cognitive Care

Iktos named Top BioTech and Life Sciences Companies of 2025

Iktos Enters Strategic €1B+ Multi-Target AI Partnership with Servier to Advance Drug Discovery in Oncology and Neurology

Pierre Fabre Laboratories and Iktos announce Integrated Drug Discovery Collaboration

DISCO Pharmaceuticals Enters License Agreement to Advance Novel Cancer Surfaceome Targeted Therapies

M Ventures: Pharma CVC and biotech innovation in 2026

NRG Therapeutics Announces First Participants Dosed in its First-in-Human Phase 1 Clinical Trial of NRG5051 Which is Being Developed as a Disease-modifying Treatment for ALS/MND and Parkinson’s

M Ventures co-leads Cyllene Therapeutics' €33 million Series C raise alongside GordonMD.